down arrow

Hyloris Pharmaceuticals SA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: BE0974363955
EUR
6.08
0.18 (3.05%)

Dec 04

BRU

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
UCB SA
Hyloris Pharmaceuticals SA
Mithra Pharmaceuticals SA
Oxurion NV
BioSenic SA
Why is Hyloris Pharmaceuticals SA ?
1
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0%
  • Poor long term growth as Operating profit has grown by an annual rate 0.35% of over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -11.97
2
Flat results in Dec 24
  • INTEREST(HY) At EUR 0.29 MM has Grown at 58.38%
  • DEBT-EQUITY RATIO (HY) Highest at -57.28 %
  • CASH AND EQV(HY) Lowest at EUR 23.59 MM
3
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 21.12%, its profits have risen by 46.6%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Hyloris Pharmaceuticals SA for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Hyloris Pharmaceuticals SA
21.12%
-0.95
50.57%
Belgium BEL 20
17.57%
1.10
15.92%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
30.55%
EBIT Growth (5y)
0.35%
EBIT to Interest (avg)
-11.97
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.62
Sales to Capital Employed (avg)
0.09
Tax Ratio
9.58%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.62
EV to EBIT
-19.76
EV to EBITDA
-21.62
EV to Capital Employed
9.73
EV to Sales
20.32
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-49.25%
ROE (Latest)
-22.33%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

Icon
Not enough Data to analyse Financial Trend
Icon
Not enough Data to analyse Financial Trend
Here's what is working for Hyloris Pharmaceuticals SA
Operating Profit
Highest at EUR -2.9 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (EUR MM)

Pre-Tax Profit
Highest at EUR -3.08 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (EUR MM)

Pre-Tax Profit
At EUR -3.08 MM has Grown at 65%
Year on Year (YoY)
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (EUR MM)

Net Profit
Highest at EUR -2.88 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (EUR MM)

Net Profit
At EUR -2.88 MM has Grown at 66.39%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is positive

Net Profit (EUR MM)

EPS
Highest at EUR -0.1
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (EUR)

Debtors Turnover Ratio
Highest at 1.65%
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost
Fallen by 1.92% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Hyloris Pharmaceuticals SA
Interest
At EUR 0.29 MM has Grown at 58.38%
over previous Semi-Annual period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (EUR MM)

Debt-Equity Ratio
Highest at -57.28 % and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Cash and Eqv
Lowest at EUR 23.59 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."